Why the study?
Whether heart failure treatments improve the blood pressure response to physical activity in an ambulatory setting had not been resolved.
Does left ventricular reverse remodeling improve actisensitivity (blood pressure reactivity to physical activity) in a patient with heart failure?
Does left ventricular reverse remodeling improve actisensitivity (blood pressure reactivity to physical activity) in a patient with heart failure?
Actisensitivity, measured by a novel multisensor ambulatory blood pressure monitor, improved following left ventricular reverse remodeling in a heart failure patient, suggesting its potential utility for estimating cardiac systolic function.
Answers are grounded in this paper and cite their sources.
Actisensitivity may track LV reverse remodeling in HF; hypothesis-generating from one case and requires prospective validation.
Blood pressure (BP) fluctuates throughout the 24-hour day as a result of the body’s responses to environmental, physical, and emotional factors. During the daytime, physical activity is one of the main determinants of BP.1 In clinical practice, ambulatory BP monitoring (ABPM) can detect BP variability (BPV) throughout the 24-hour day. Studies that simultaneously performed ABPM and actigraphy showed positive association between physical activity and BP during the daytime in both healthy and hypertensive populations.2,3 Heart failure (HF) involves low cardiac output and autonomic nervous dysfunction,4 which may lead to a pathological BP response to physical activity. In laboratory settings, the exercise stress test for HF patients demonstrates a lesser BP response to the exercise load, which indicates the severity of HF.5 The question of whether HF treatments improve the BP response to physical activity has not been resolved. Left ventricular reverse remodeling (LVRR), defined as an improvement of echocardiographic left ventricular ejection fraction (LVEF) or shrinking of the left ventricular end-diastolic diameter (LVDd), is often observed in the clinical course of HF patients.6,7 LVRR represents the improvement of cardiac output, and thus changes in the BP response to physical activity may be observed before and after LVRR. Here, we report a case of a change in BPV as determined by BP reactivity in response to physical activity from before to after LVRR under an ambulatory setting. We propose this BP reactivity against physical activity as “actisensitivity,” which is a new concept of BPV evaluated by an information and communication technology (ICT)-based multisensor BP monitoring system-ABPM (IMS-ABPM) (TM-2441, A&D Co., Tokyo).8,9Figure 1 shows the characteristics of IMS-ABPM, which is a new device equipped with (i) a highly sensitive actigraph that can detect the wearer’s fine-scale physical movements in three-directions, (ii) a thermometer, and (iii) a barometer (Supplementary Materials). The IMS-ABPM device (#TM-2441, A&D, Tokyo) and an example case for actisensitivity. Upper figure: The IMS-ABPM is a new device equipped with (i) a highly sensitive actigraph that can detect the wearer’s fine-scale physical movements in three directions, (ii) a thermometer, and (iii) a barometer. Lower figure: This figure demonstrates a representative case of actisensitivity in a hypertensive patient, a 75-year-old female without marked cardiac disease. The dotted line indicates the regression line of the actisensitivity in this figure. The actisensitivity of ambulatory BP is defined as the slope of the BP change against the physical activity in the daytime. The regression line is calculated from the daytime ambulatory systolic BP as the vertical axis and the corresponding log-transformed 5-minute averages of physical activity (G) just before each BP measurement as the horizontal axis. Abbreviations: BP, blood pressure; IMS-ABPM, information and communication technology–based multisensor BP monitoring system. A 38-year-old obese man presented with effort dyspnea that had begun ~6 months earlier. His past and familial medical history did not include notable cardiac disease. On physical examination, his height was 178 cm; body weight, 124 kg; body mass index, 39.3 kg/m2; BP, 206/145 mm Hg; pulse rate, 124 beats/minute with regularity; oxygen saturation 94% (room air); coarse crackle; and edema in both lower extremities. A 12-lead electrocardiogram showed no ischemic ST change and no findings of left ventricular hypertrophy. The initial laboratory findings showed elevated B-type natriuretic peptide (BNP) at 533.3 pg/mL (reference range [RR] <18.4 pg/mL), mildly elevated liver function and serum creatinine level. A chest X-ray revealed cardiac dilatation, and echocardiography showed a reduced LVEF of 27% and left ventricular and atrial dilatation as a left ventricular end-diastolic/systolic dia. (LVDd/s) of 59/53 mm; left atrial dia., 60 mm; both septum and posterior wall, 12 mm. In addition, coronary artery angiography revealed no significant stenosis. The results of various diagnostic examinations for secondary hypertension including those for aldosteronism, renovascular disorders, and pheochromocytoma were within normal ranges. However, sleep polysomnography (PSG) revealed severe obstructive sleep apnea (OSA): apnea and hypoventilation index (AHI), 42.9/hour. Based on these findings, we diagnosed congestive HF due to hypertensive heart disease complicated with OSA. The administration of a beta-blocker (carvedilol 10 mg/day), an angiotensin receptor blocker (olmesartan 40 mg/day), and a loop diuretic (azosemide 30 mg/day) was initiated, and the patient’s symptoms (e.g., fatigue and edema) were alleviated immediately. At 6 months after his discharge, we continued the management of the patient’s HF, and his 24-hour ABP level decreased from 144/99 to 132/89 mm Hg and his body weight also decreased from 124 to 95 kg. We again conducted an echocardiography exam, which revealed LVRR as decreasing left ventricular dias. (LVDd/s, 50/35 mm) and improved LVEF of 56%. Moreover, follow-up PSG showed improved OSA and decreased AHI (from 42.9 to 15.0/hour) without the need for or use of nighttime noninvasive positive pressure ventilation. We conducted IMS-ABPM measurements both before and after the improvement of the patient’s cardiac function, that is, LVRR. The baseline measurement was conducted before his discharge, and the follow-up measurement was 6 months post-discharge when LVRR had already been observed. These 2 IMS-ABPM measurements revealed the improvement of actisensitivity. As explained in Figure 1, we define “actisensitivity” as the slope of changes in daytime ABP against physical activity, which is calculated as the slope of the correlation line with ambulatory systolic BP (SBP) values between each measurement as the vertical axis and the log-transformed 5-minute average values of physical activity (G) just before BP measurements as the horizontal axis. The details of the concept of “actisensitivity” and the method of the measurement of physical activity by actigraphy are described in the Supplementary Materials. Figure 2 shows our patient’s ABP levels and physical activities assessed by IMS-ABPM at the baseline and at the follow-up. As illustrated in Figure 3, actisensitivity improved the slope in the regression line: β = 0.34 to 4.79, which indicates that the increment in ABP in response to physical activity was greater after LVRR (i.e., improved LVEF) compared to before LVRR. The measured values of ambulatory SBP and physical activity at the baseline and the follow-up are shown in Supplementary Figure S1. However, daytime ambulatory BP variability (ABPV) measured as the coefficient of variation (CV) in the patient’s SBP did not increase between the baseline and follow-up (daytime ambulatory SBP-CV at baseline, 0.14; at follow-up, 0.12). The change in ambulatory BP levels from before to after the improvement of cardiac systolic function (left ventricular reverse remodeling). The IMS-ABPM results before and after the LVRR are shown. The changes in ambulatory BP levels against physical activity are evident. The ambulatory BP variability measured as the CV in systolic BP did not increase from before to after the LVRR (daytime ambulatory systolic BP-CV at baseline, 0.14; at follow-up, 0.12). Abbreviations: BP, blood pressure; CV, coefficient of variation; IMS-ABPM, information and communication technology–based multisensor BP monitoring system; LVRR, left ventricular reverse remodeling. The change in actisensitivity from before to after the left ventricular reverse remodeling. An improvement of the actisensitivity after LVRR was observed (before, β = 0.34; after, β = 4.79). Actisensitivity of ambulatory BP is defined as the slope of the regression line which is calculated from daytime ambulatory systolic BPs with the log-transformed corresponding 5-minute average of physical activity just before each BP measurement. The dotted line and solid line indicate the regression line of the actisensitivity before and after LVRR, respectively. Abbreviations: BP, blood pressure; LVRR, left ventricular reverse remodeling. This is the first case report of the change in a patient’s BP reactivity in response to physical activity under ambulatory condition from before to after LVRR (i.e., improvement of cardiac systolic function) using a new device, IMS-ABPM. Our patient’s actisensitivity was increased after LVRR, which indicated that BP reactivity in response to physical activity was improved corresponding to the improvement of cardiac systolic function. Actisensitivity may therefore be useful for the estimation of cardiac systolic function in HF patients. Increased BP in response to physical activity is a physiological response.10 In healthy individuals, physical activity increases the body’s sympathetic nervous activity, which leads to vasoconstriction and increased cardiac output to maintain organ circulation.10 In contrast, although the mechanisms of the decreased BP reactivity against physical activity in HF patients has been unclear,4,11,12 decreased cardiac systolic function and abnormal sympathetic activity may suppress the elevation of BP in response to physical activity. It was reported that compared to HF patients with reduced LVEF, HF patients with preserved LVEF exhibited elevated BP in response to physical activity.11 Our present findings showed that the improvement of the EF provided increased BP in response to physical activity even in the ambulatory setting in a patient with HF and developing LVRR. A decreased peak BP level during exercise in a laboratory setting has been marker of poor prognosis in HF patients with a reduced LVEF.5,12 Our observation of increased BP in response to physical activity detected by IMS-ABPM may also indicate a better prognosis in HF patients. During the follow-up of our patient, a beta blocker and angiotensin receptor blocker were used to control his BP. These drugs are standard not only for BP control but also as HF treatment. Physicians may not always use these appropriate drugs in the treatment of heart failure, because HF patients often show low BP levels. In a meta-analysis of registry data, Raphael et al.13 reported the paradoxical phenomenon of elevated BP levels in HF patients; that is, decreased systolic BP was a marker of poor prognosis in patients with chronic HF. Elevated BP levels at the onset of HF, which suggests the need for appropriate medication, might be a predictor of the development of LVRR. Our patient’s daytime ambulatory systolic BP-CV (SBP-CV) did not change after the improvement of his cardiac systolic function. The SBP-CV is one of the conventional indices that indicate BP variability.14 Although an association has been reported between increased ABPV and organ damage or cardiovascular events in general and hypertensive populations,15,16 such an association in selected populations was controversial. Lower daytime ABPV has been reported to be associated with poor prognosis in HF patients with reduced LVEF.17 Our present findings suggest that actisensitivity may detect cardiac systolic function more sensitively and be clinically meaningful than conventional daytime ABPV. In conclusion, we observed an HF patient’s improved actisensitivity with the clinical course of LVRR by using a new device, that is, IMS-ABPM. The BP reactivity in response to physical activity evaluated by IMS-ABPM may be useful for the estimation of cardiac systolic function in HF patients. We gratefully acknowledge the IMS-ABPM (#TM-2441) development group at A&D Co. (Tokyo). No funding from any funding agency in the public, commercial, or not-for-profit sectors was involved in this case report. K. Kario has received research funding from Omron Healthcare Co., Fukuda Denshi, and A&D Co. The authors declared no conflict of interest.
No takes yet. Share an insight, caveat, or question.
Narita et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: